Beam Therapeutics reported promising efficacy in November for the first four sickle cell disease (SCD) patients treated with its base edited cell therapy BEAM-101 in the ongoing Phase I/II BEACON clinical trial, despite one death associated with busulfan conditioning used to prepare patients for treatment. In data reported on 8 December at the American Society of Hematology (ASH) annual meeting in San Diego, efficacy seen in three more patients was consistent with the first four, without another major busulfan-related event.
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up
Next-Gen Program Aims To ESCAPE Busulfan Conditioning
Beam presented data from three more patients than during its last update for BEAM-101, showing stem cell engraftment and efficacy consistent with the first four patients.
